LONDON — The United Kingdom is set to take a significant step in its debate over assisted dying as lawmakers prepare to vote on a proposed bill on Friday. If passed, the legislation would allow terminally ill adults in England and Wales to request medical assistance to end their lives, placing the UK among a small number of European nations with such laws.

The proposed bill outlines strict safeguards to prevent abuse, including the requirement for individuals to have the mental capacity to make the decision, provide two formal declarations of their intent, undergo evaluations by two doctors within a week, and receive approval from a high court judge. Eligibility would be limited to adults with a life expectancy of six months or less, who would self-administer an approved substance to end their lives.

This draft legislation has reignited discussions about the ethical, legal, and societal implications of assisted dying in the UK. Proponents argue for the right to choose how and when to die, while critics emphasize the need to protect vulnerable individuals from coercion.

Assisted Dying in Europe

Across Europe, only a handful of countries permit euthanasia or assisted suicide, with many implementing such laws relatively recently.

The Netherlands was the first nation globally to legalize euthanasia in 2002, under strict conditions ensuring that the patient’s request is voluntary and well-informed, their suffering is unbearable with no prospect of improvement, and all alternatives have been exhausted. Minors aged 12 and above may also request euthanasia with parental consent.

Belgium followed shortly after, adopting a similar law in 2002, which it later extended to minors in 2014. Luxembourg decriminalized euthanasia and assisted suicide in 2009, and Spain introduced legislation in 2021 for individuals experiencing unbearable suffering.

In Portugal, a long-debated euthanasia bill was passed in 2023 despite initial vetoes by the president. Meanwhile, Germany and Austria changed their laws following constitutional rulings that upheld the right to self-determination in end-of-life decisions.

Ongoing Debates

While some European nations have embraced assisted dying, others remain divided. Ireland’s parliament is considering recommendations for legalizing assisted dying, while France is set to debate comprehensive legislation in 2025.

In the UK, where assisted suicide and euthanasia are currently illegal, this legislative push represents a critical moment in a decades-long debate. Advocates and critics alike are watching closely as lawmakers decide whether the UK will join its European counterparts in legalizing the practice under controlled circumstances.

The vote is expected to draw widespread attention, reflecting the growing global conversation about autonomy, dignity, and the ethics of end-of-life care.

A new treatment approach for asthma and chronic obstructive pulmonary disease (COPD) has been identified by scientists in the UK, marking what is being hailed as the first major advancement in managing these conditions in half a century.

The findings, published in The Lancet Respiratory Medicine, reveal that a single injection of benralizumab, a monoclonal antibody, is significantly more effective than traditional steroid tablets in reducing symptom flare-ups, known as eosinophilic exacerbations. These episodes account for roughly 50% of asthma attacks and 30% of COPD attacks, causing symptoms such as wheezing, coughing, and chest tightness.

A New Approach to Inflammation

Steroid tablets, the conventional treatment, work by reducing inflammation in the lungs but are not effective for all patients and can lead to serious long-term side effects like high blood pressure and osteoporosis. In contrast, benralizumab targets white blood cells to reduce lung inflammation, curbing symptoms and lowering the need for additional treatments by 30%, according to the study.

“This could be a game-changer for people with asthma and COPD,” said Dr. Mona Bafadhel, lead investigator and chair of respiratory medicine at King’s College London.

Widespread Impact

COPD affects an estimated 36.6 million Europeans, while nearly 10 million people under 45 have asthma. These conditions significantly impact patients’ quality of life, particularly older individuals with both diseases, who often face limited life expectancies.

“We need to provide these patients with life-saving options before their time runs out,” said Dr. Sanjay Ramakrishnan, a study author and clinical senior lecturer at the University of Western Australia. He criticized current treatments as being “stuck in the 20th century.”

Trial Highlights

The study divided high-risk asthma and COPD patients into three groups: one received benralizumab, another steroids, and the third both treatments.

After 28 days, those treated with benralizumab showed better respiratory outcomes. At the 90-day mark, 74% of steroid-treated patients required further medical intervention due to treatment failure, compared to only 45% of those who received the antibody injection.

The findings suggest that a single benralizumab injection could become a vital emergency treatment, reducing hospital readmissions for asthma and COPD patients.

A Pivotal Moment in Respiratory Care

“We hope these pivotal studies will change how asthma and COPD exacerbations are treated for the future, ultimately improving the health for over a billion people living with asthma and COPD across the world,” Bafadhel stated.

The trial, supported by AstraZeneca and the University of Oxford, offers renewed hope for better management of respiratory diseases, potentially transforming care for millions globally.

U.S. President-elect Donald Trump has nominated Dr. Jay Bhattacharya, a Stanford University health economist and prominent critic of COVID-19 lockdowns and vaccine mandates, to head the National Institutes of Health (NIH). Bhattacharya’s appointment signals a potential shift in the agency’s direction as Trump prepares for his second term.

In a statement, Trump said Bhattacharya, 56, will collaborate with Robert F. Kennedy Jr., his nominee to lead the Department of Health and Human Services, to address the nation’s pressing health challenges. “Together, Jay and RFK Jr. will restore the NIH to a gold standard of medical research, addressing chronic illnesses and advancing solutions to save lives,” Trump said.

Reshaping the NIH

The NIH, a division of the Department of Health and Human Services, oversees a $48 billion budget, funding critical biomedical research on vaccines, cancer, and other diseases. It also conducts internal research through its extensive network of scientists. Bhattacharya has vowed to restore public trust in the agency, pledging reforms to enhance its transparency and focus.

In a post on X, formerly Twitter, Bhattacharya said he was “honored and humbled” by the nomination. “We will reform American scientific institutions to make them worthy of trust again and ensure that science is harnessed to improve the health of all Americans,” he stated.

A Controversial Background

Bhattacharya co-authored the Great Barrington Declaration in October 2020, which criticized widespread lockdowns during the pandemic. The declaration advocated for achieving herd immunity by allowing low-risk individuals to lead normal lives while protecting those at higher risk. This approach sparked widespread debate, with critics, including former NIH Director Dr. Francis Collins, labeling it as dangerous and outside mainstream science.

Bhattacharya has remained vocal about his opposition to lockdowns, calling them “the single biggest public health mistake” during a panel discussion in March 2021. His nomination underscores the continuing political and scientific divisions stemming from the pandemic.

Challenges and Approvals Ahead

Bhattacharya’s nomination will require Senate approval, as will Trump’s other health appointees, including Kennedy for the Department of Health and Human Services, Dr. Mehmet Oz for the Centers for Medicare and Medicaid Services, and Dr. Marty Makary for the Food and Drug Administration.

As the U.S. health landscape faces challenges ranging from chronic disease to emerging infectious threats, Bhattacharya’s leadership at the NIH is expected to provoke both scrutiny and significant debate over the future direction of American biomedical research.